

# John D Davis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/613588/publications.pdf>

Version: 2024-02-01

68  
papers

4,992  
citations

172457

29  
h-index

102487

66  
g-index

76  
all docs

76  
docs citations

76  
times ranked

7395  
citing authors

#	ARTICLE	IF	CITATIONS
1	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 238-251.	27.0	1,483
2	REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, e81.	27.0	487
3	Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1184-1195.	27.0	371
4	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 44.	4.1	297
5	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 459-473.	1.5	288
6	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1282-1293.	1.2	214
7	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 377-388.	1.2	155
8	Dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: results from a phase 3 open-label trial and subsequent phase 3 open-label extension. <i>British Journal of Dermatology</i> , 2020, 182, 85-96.	1.5	111
9	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 131.	4.1	110
10	Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 432.	7.4	81
11	Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of <i>in silico</i> physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. <i>Xenobiotica</i> , 2008, 38, 620-640.	1.1	64
12	A Holistic Strategy for Characterizing the Safety of Metabolites through Drug Discovery and Development. <i>Chemical Research in Toxicology</i> , 2009, 22, 1653-1662.	3.3	63
13	Grapefruit Juice-Drug Interaction Studies as a Method to Assess the Extent of Intestinal Availability: Utility and Limitations. <i>Current Drug Metabolism</i> , 2008, 9, 785-795.	1.2	61
14	Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 51-65.	1.9	57
15	Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL-4R $\alpha$ , in Atopic Dermatitis Patients and Normal Volunteers. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 617-624.	2.5	57
16	A phase 2, open-label study of single-dose dupilumab in children aged 6 months to 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 464-475.	2.4	52
17	In vivo-in vitro correlation (IVIVC) modeling incorporating a convolution step. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2001, 28, 277-298.	1.8	51
18	Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. <i>Antiviral Therapy</i> , 2009, 14, 831-837.	1.0	44

#	ARTICLE	IF	CITATIONS
19	Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from) Tj ETQq1 1 0 7843144 rgBT /Overlock 10 Tf 50 57 Td (tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-2,3,4-trimethoxy-1,2,3,4-tetrahydroquinoline-5-carboxamide hydrochloride. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 114-124.	10.7	8431
20	A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014, 3, 1-9.	2.5	40
21	Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. <i>Aids</i> , 2009, 23, 2115-2122.	2.2	39
22	Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1146-1154.	4.7	39
23	Simultaneous assay of fluoroquinolones and theophylline in plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1993, 621, 105-109.	1.7	37
24	Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 742-755.	1.6	36
25	A Comparison of the Prediction Accuracy of Two IVVC Modelling Techniques. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 3422-3432.	3.3	35
26	Scintigraphic Study to Investigate the Effect of Food on a HPMC Modified Release Formulation of UK-294,315. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1568-1576.	3.3	33
27	Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 68-75.	2.4	32
28	Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2290-2296.	3.2	32
29	Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMab), in patients with advanced solid tumors. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1103-1111.	2.0	31
30	NONLINEAR ORAL PHARMACOKINETICS OF THE $\pm$ -ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 197-204.	3.3	29
31	Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1424-1431.	2.0	27
32	Interpretation and Optimization of the Dissolution Specifications for a Modified Release Product with an In Vivo-In Vitro Correlation (IVVC). <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 571-581.	3.3	20
33	Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach. <i>Journal of Lipid Research</i> , 2016, 57, 46-55.	4.2	18
34	Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 336-345.	2.4	17
35	Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. <i>AAPS Journal</i> , 2015, 17, 881-890.	4.4	17
36	Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the $\pm$ -Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-2,3,4-trimethoxy-1,2,3,4-tetrahydroquinoline-5-carboxamide hydrochloride. <i>Drug Metabolism and Disposition</i> , 2008, 36, 87-94.	3.3	15

#	ARTICLE	IF	CITATIONS
37	Effect of Rifampin and Rifabutin on the Pharmacokinetics of Lersivirine and Effect of Lersivirine on the Pharmacokinetics of Rifabutin and 25-O-Desacetyl-Rifabutin in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4303-4309.	3.2	15
38	Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 495-497.	2.5	15
39	Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 479-494.	1.8	15
40	Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials. <i>Journal of Drugs in Dermatology</i> , 2019, 18, 804-813.	0.8	15
41	Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations. <i>Xenobiotica</i> , 2009, 39, 534-543.	1.1	14
42	Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 768-775.	2.4	14
43	Phase 1 Study Evaluating Safety, Tolerability, Pharmacokinetics and Immunogenicity of REGN2222 in Healthy Adults: A New Human Monoclonal RSV-F Antibody for RSV Prevention. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.9	14
44	Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 90-104.	2.0	14
45	Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition. <i>Pharmaceutical Research</i> , 1994, 11, 1424-1428.	3.5	13
46	The Use of Beat-to-Beat Electrocardiogram Analysis to Distinguish QT/QTc Interval Changes Caused by Moxifloxacin From Those Caused by Vardenafil. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 449-454.	4.7	11
47	A population approach to in vitro-in vivo correlation modelling for compounds with nonlinear kinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 317-332.	1.8	10
48	The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1567-1572.	1.9	10
49	Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 756-767.	1.6	10
50	Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. <i>Pharmaceutical Research</i> , 1995, 12, 257-262.	3.5	9
51	Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 941-952.	2.5	8
52	The Effects of Averaging on Accuracy of IVIVC Model Predictions. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 3829-3838.	3.3	7
53	Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. <i>Clinical Therapeutics</i> , 2010, 32, 1889-1895.	2.5	7
54	Combining Bottom-up and Top-down Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC0941) Pharmacokinetics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 747-755.	2.5	7

#	ARTICLE	IF	CITATIONS
55	Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 405-414.	2.5	7
56	Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. <i>Advances in Therapy</i> , 2021, 38, 2365-2378.	2.9	7
57	Pharmacokinetics and Concentration-Response of Dupilumab in Patients With Seasonal Allergic Rhinitis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 689-695.	2.0	7
58	Pharmacokinetic Effects of Coadministration of Lersivirine with Raltegravir or Maraviroc in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 887-892.	3.2	6
59	The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1318-1328.	4.7	6
60	Metabolism of theophylline and its inhibition by fluoroquinolones in rat hepatic microsomes. <i>Xenobiotica</i> , 1995, 25, 563-573.	1.1	4
61	Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children $\geq 6$ to $< 12$ Years of Age Using Phase 3 Data. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1345-1357.	1.6	4
62	Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1412-1421.	2.5	4
63	REGEN-COV <sup>®</sup> antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification. <i>Bioanalysis</i> , 2021, 13, 1827-1836.	1.5	4
64	The Pharmacokinetics of Lersivirine (UK-453,061) and HIV-1 Protease Inhibitor Coadministration in Healthy Subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 24-32.	2.1	3
65	Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe. <i>Clinical Pharmacology in Drug Development</i> , 2022, . .	1.6	3
66	14148 Pharmacokinetics, safety, and efficacy of dupilumab in children aged $\geq 2$ to $< 6$ years with severe uncontrolled atopic dermatitis (LIBERTY AD PRE-SCHOOL). <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB19.	1.2	2
67	A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1332-1342.	2.5	2
68	Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3398-3407.	2.4	1